KR880013553A - 개선된 상 분리 마이크로캡슐화 방법 및 그로부터 제조된 제약학적 조성물 - Google Patents

개선된 상 분리 마이크로캡슐화 방법 및 그로부터 제조된 제약학적 조성물 Download PDF

Info

Publication number
KR880013553A
KR880013553A KR1019880006203A KR880006203A KR880013553A KR 880013553 A KR880013553 A KR 880013553A KR 1019880006203 A KR1019880006203 A KR 1019880006203A KR 880006203 A KR880006203 A KR 880006203A KR 880013553 A KR880013553 A KR 880013553A
Authority
KR
South Korea
Prior art keywords
core
polymer
solvent
envelope
biocompatible
Prior art date
Application number
KR1019880006203A
Other languages
English (en)
Other versions
KR970001209B1 (ko
Inventor
로늘드 로터 제임즈
저라아드 랜질로티 마이클
Original Assignee
알퐁스 아아르 노에
아메리칸 사이아나밋드 캄파니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 알퐁스 아아르 노에, 아메리칸 사이아나밋드 캄파니 filed Critical 알퐁스 아아르 노에
Publication of KR880013553A publication Critical patent/KR880013553A/ko
Application granted granted Critical
Publication of KR970001209B1 publication Critical patent/KR970001209B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J13/00—Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided for; Making microcapsules or microballoons
    • B01J13/02—Making microcapsules or microballoons
    • B01J13/06—Making microcapsules or microballoons by phase separation
    • B01J13/12—Making microcapsules or microballoons by phase separation removing solvent from the wall-forming material solution
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J13/00—Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided for; Making microcapsules or microballoons
    • B01J13/02—Making microcapsules or microballoons
    • B01J13/20—After-treatment of capsule walls, e.g. hardening

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Glass Compositions (AREA)
  • Sampling And Sample Adjustment (AREA)
  • Physical Or Chemical Processes And Apparatus (AREA)
  • Packages (AREA)
  • Materials For Medical Uses (AREA)
  • Food Preservation Except Freezing, Refrigeration, And Drying (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polymerisation Methods In General (AREA)

Abstract

내용 없음

Description

개선된 상 분리 마이크로캡슐화 방법 및 그로부터 제조된 제약학적 조성물
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (10)

  1. 하기(a)-(c)단계를 포함하는 , 마이크로캡슐형태로 제약학적 조성물을 제조하는 방법 : (a) 생체 양립성 포봉 중합체를 함유하는 유기 용매내에 제약학적 약제로 구성된 중심물질을 함유하는 용액을 분산시키는 단계 : (b) 이 분산액에 포봉 중합체 및 중심물질에 대한 비-용제를 첨가하는 단계 : 및 (c)경화용매로서 휘발성 실리콘 유체를 사용하는 것을 특징으로하는, 제약학적 조성물의 고형 마이크로캡슐을 만들고 유기 용매를 추출하기 위해 (b)단계의 생성물을 경화용매에 첨가하는 단계.
  2. 제1항에 있어서, 하기(a)-(c)단계를 포함하는 방법 : (a) 생체양립성 포봉 중합체의 유기용매중 용액내에 고형 입자들을 포함하는 낮은 용해도의 중심물질을 분산시키는 단계 ; (b) 포봉 중합체 및 중심물질에 대한 비-용제(이 비용제는 유기용매에 용해성임)을 첨가하면서, (a)에서 제조된 분산액을 휘저어 섞음으로써, 근본적으로 유기 용매에 포봉 중합체의 농축된 용액으로 구성된 액체상으로서 포봉 중합체가 용액으로부터 분리되고 선택적으로 중심물질 입자를 코우팅 처리하는 단계 ; 및 (c) 위발성 실리콘 유체를 포함하는 경화제를 (b)단계의 코우팅처리된 중심 입자 분산액에 첨가하는 단계.
  3. 제1항 또는 제2항에 있어서, 생체양립성 포봉 중합체가 생체분해성이기도하며, 비타민이 비타민B12이고 비-용제가 포봉 중합체와는 상용성이 아닌 부차적인 중합체인 방법.
  4. 제1항 내지 제2항에 있어서, 중심물질이 테트라사이클린, 독시사이클린, 미노사이클린, 메타사이클린, 데클로마이신, 옥시테트라사이클린, 또는 클로르테트라사이클린 또는 제약학적으로 허용가능한 그의 염인 방법.
  5. 제1항 내지 제2항에 있어서, 중심물질이 세팔로스포린, 페니실린, 퀴놀린, 아미노글리코시드 또는 페니실린과 베타락팀의 혼합물인 방법.
  6. 제1항 내지 제2항에 있어서, 중심물질이 펩티드 또는 제약학적으로 허용가능한 그의 염을 포함하는 방법.
  7. 제1항 내지 제2항에 있어서 중심물질이 단백질 또는 제약학적으로 허용가능한 염을 포함하는 방법.
  8. 제1항에 있어서, 중심물질이 마취제를 포함하는 방법.
  9. 하기(a)-(b)를 포함하며 약3중량%이하의 잔류 경화제 함량을 갖는, 마이크로캡슐 형태로 상 분리방법에 의해 제조된, 연장된 기간에 걸쳐 유효량의 약제가 지속적으로 방출되게 하기에 적합한 제약학적 조성물 ; (a) 통상적인 단일 적용량보다는 많은 유효한 양으로 최소한 하나의 제약학적 약제 ; 및 (b) 생체양립성 포봉 중합체.
  10. 하기(a)-(b)를 포함하며 약3중량%이하의 잔류 경화제 함량을 갖는, 마이크로캡슐 형태로 제1항 또는 제2항의 상 분리방법에 의해 제조된, 연장된 기간에 걸쳐, 유효량의 약재가 지속적으로 방출되게 하기에 적합한 제약학적 조성물 ; (a) 통상적인 단일 적용량보다는 많은 유효한 양으로 최소한 하나의 제약학적 약제 ; 및 (b) 생체양립성 포봉 중합체.
    ※ 참고사항 : 최초출원내용에 의하여 공개하는 것임.
KR1019880006203A 1987-05-26 1988-05-26 개선된 상 분리 마이크로캡슐화 방법 및 그로부터 제조된 제약학적 조성물 KR970001209B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/054,372 1987-05-26
US07/054,372 US5000886A (en) 1987-05-26 1987-05-26 Silicone-hardened pharmaceutical microcapsules and process of making the same

Publications (2)

Publication Number Publication Date
KR880013553A true KR880013553A (ko) 1988-12-21
KR970001209B1 KR970001209B1 (ko) 1997-02-04

Family

ID=21990585

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019880006203A KR970001209B1 (ko) 1987-05-26 1988-05-26 개선된 상 분리 마이크로캡슐화 방법 및 그로부터 제조된 제약학적 조성물

Country Status (19)

Country Link
US (1) US5000886A (ko)
EP (1) EP0292710B1 (ko)
JP (1) JP2712101B2 (ko)
KR (1) KR970001209B1 (ko)
AT (1) ATE70992T1 (ko)
AU (1) AU618000B2 (ko)
BR (1) BR1100810A (ko)
CA (1) CA1330533C (ko)
DE (1) DE3867313D1 (ko)
DK (1) DK169119B1 (ko)
ES (1) ES2038236T3 (ko)
GR (1) GR3004186T3 (ko)
HK (1) HK116493A (ko)
IE (1) IE61338B1 (ko)
IL (1) IL86274A (ko)
NO (1) NO177984C (ko)
NZ (1) NZ224722A (ko)
PH (1) PH27019A (ko)
ZA (1) ZA883737B (ko)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030161889A1 (en) * 1984-03-16 2003-08-28 Reid Robert H. Vaccines against diseases caused by enteropathogenic organisms using antigens encapsulated within biodegradable-biocompatible microspheres
US5693343A (en) 1984-03-16 1997-12-02 The United States Of America As Represented By The Secretary Of The Army Microparticle carriers of maximal uptake capacity by both M cells and non-M cells
US6410056B1 (en) 1984-03-16 2002-06-25 The United States Of America As Represented By The Secretary Of The Army Chemotherapeutic treatment of bacterial infections with an antibiotic encapsulated within a biodegradable polymeric matrix
USRE40786E1 (en) 1984-03-16 2009-06-23 The United States Of America As Represented By The Secretary Of The Army Vaccines against intracellular pathogens using antigens encapsulated within biodegradable-biocompatible microspheres
US6309669B1 (en) 1984-03-16 2001-10-30 The United States Of America As Represented By The Secretary Of The Army Therapeutic treatment and prevention of infections with a bioactive materials encapsulated within a biodegradable-biocompatible polymeric matrix
US6217911B1 (en) 1995-05-22 2001-04-17 The United States Of America As Represented By The Secretary Of The Army sustained release non-steroidal, anti-inflammatory and lidocaine PLGA microspheres
US5811128A (en) * 1986-10-24 1998-09-22 Southern Research Institute Method for oral or rectal delivery of microencapsulated vaccines and compositions therefor
US5985354A (en) 1995-06-07 1999-11-16 Brown University Research Foundation Preparation of multiwall polymeric microcapsules from hydrophilic polymers
US5143661A (en) * 1987-05-26 1992-09-01 American Cyanamid Company Silicone-hardened pharmaceutical microcapsules
ATE105177T1 (de) * 1988-12-22 1994-05-15 American Cyanamid Co Verfahren zur behandlung von periodontitis durch protrahierte wirkstoffabgabe von arzneimitteln in der zahnhoehle, zusammensetzung davon und vorrichtung zur verabreichung.
EP0374532B1 (en) * 1988-12-22 1994-09-21 American Cyanamid Company Improved phase separation-microencapsulated pharmaceutical compositions useful for alleviating dental disease
AU8303691A (en) 1991-04-24 1992-12-21 United States Of America, As Represented By The Secretary Of The Army, The Oral-intestinal vaccines against diseases caused by enteropathogenic organisms using antigens encapsulated within biodegradable-biocompatible microspheres
CH683149A5 (fr) * 1991-07-22 1994-01-31 Debio Rech Pharma Sa Procédé pour la préparation de microsphères en matériau polymère biodégradable.
DE4223169C1 (de) * 1992-07-10 1993-11-25 Ferring Arzneimittel Gmbh Verfahren zur Mikroverkapselung wasserlöslicher Wirkstoffe
US5922340A (en) 1992-09-10 1999-07-13 Children's Medical Center Corporation High load formulations and methods for providing prolonged local anesthesia
DE4239244A1 (de) * 1992-11-21 1994-05-26 Basf Ag Retard-Form für pharmazeutische Wirkstoffe
US6939546B2 (en) 1993-05-21 2005-09-06 The United States Of America As Represented By The Secretary Of The Army Model for testing immunogenicity of peptides
US5512278A (en) * 1994-01-11 1996-04-30 Phylomed Corporation Ointment base useful for pharmaceutical preparations
US6447796B1 (en) 1994-05-16 2002-09-10 The United States Of America As Represented By The Secretary Of The Army Sustained release hydrophobic bioactive PLGA microspheres
US6855331B2 (en) 1994-05-16 2005-02-15 The United States Of America As Represented By The Secretary Of The Army Sustained release hydrophobic bioactive PLGA microspheres
US7033608B1 (en) 1995-05-22 2006-04-25 The United States Of America As Represented By The Secretary Of The Army “Burst-free” sustained release poly-(lactide/glycolide) microspheres
US6902743B1 (en) 1995-05-22 2005-06-07 The United States Of America As Represented By The Secretary Of The Army Therapeutic treatment and prevention of infections with a bioactive material(s) encapuslated within a biodegradable-bio-compatable polymeric matrix
AU706541B2 (en) 1995-06-09 1999-06-17 Euro-Celtique S.A. Formulations and methods for providing prolonged local anesthesia
JP2909418B2 (ja) * 1995-09-18 1999-06-23 株式会社資生堂 薬物の遅延放出型マイクロスフイア
US5942253A (en) * 1995-10-12 1999-08-24 Immunex Corporation Prolonged release of GM-CSF
WO1997049391A1 (en) 1996-06-24 1997-12-31 Euro-Celtique, S.A. Methods for providing safe local anesthesia
US6046187A (en) * 1996-09-16 2000-04-04 Children's Medical Center Corporation Formulations and methods for providing prolonged local anesthesia
BR9815499A (pt) 1997-07-02 2001-01-02 Euro Celtique Sa Anestesia prolongada nas juntas e nos espacos corporais.
SE512663C2 (sv) 1997-10-23 2000-04-17 Biogram Ab Inkapslingsförfarande för aktiv substans i en bionedbrytbar polymer
GB2332374B (en) * 1997-12-19 2002-11-06 New Zealand Pastoral Agiricult Controlled release vitamin B12 compositions and methods of using them
US20030180368A1 (en) * 1998-03-14 2003-09-25 Cenes Drug Delivery Limited Production of microparticles
US6174873B1 (en) 1998-11-04 2001-01-16 Supergen, Inc. Oral administration of adenosine analogs
US6498153B1 (en) 1998-12-31 2002-12-24 Akzo Nobel N.V. Extended release growth promoting two component composition
US6824822B2 (en) * 2001-08-31 2004-11-30 Alkermes Controlled Therapeutics Inc. Ii Residual solvent extraction method and microparticles produced thereby
CZ20031262A3 (en) * 2000-10-16 2004-03-17 Neopharm, Inc. Liposomal formulation of mitoxantrone
EP1363602A4 (en) * 2001-01-25 2006-01-11 Euro Celtique Sa LOCAL ANESTHESIA, AND METHOD OF USE
WO2002094321A1 (fr) * 2001-05-23 2002-11-28 Tanabe Seiyaku Co., Ltd. Compositions favorisant la guérison d'une fracture osseuse
ES2427930T3 (es) * 2001-05-23 2013-11-04 Mitsubishi Tanabe Pharma Corporation Composición terapéutica para el tratamiento regenerativo de enfermedades de los cartílagos
DE10141650C1 (de) 2001-08-24 2002-11-28 Lohmann Therapie Syst Lts Transdermales Therapeutisches System mit Fentanyl bzw. verwandten Substanzen
US6682348B2 (en) 2002-03-29 2004-01-27 Orapharma, Inc. Dispensing apparatus and cartridge
CA2504268A1 (en) * 2002-10-30 2004-11-18 Spherics, Inc. Nanoparticulate bioactive agents
PT2316456T (pt) 2003-04-29 2017-09-05 Orexigen Therapeutics Inc Composições para afetar a perda de peso compreendendo naltrexona e bupropion
US20050048115A1 (en) * 2003-08-27 2005-03-03 Murty Mangena Buprenorphine microspheres
WO2007067341A2 (en) 2005-11-22 2007-06-14 Orexigen Therapeutics, Inc. Compositions and methods for increasing insulin sensitivity
WO2007089318A2 (en) * 2005-11-23 2007-08-09 Orexigen Therapeutics, Inc. Compositions and methods for reducing food cravings
US8916195B2 (en) * 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
US9119902B2 (en) * 2006-06-22 2015-09-01 Ethicon, Inc. Semi-crystalline absorbable microspheres
US8580307B2 (en) 2006-06-22 2013-11-12 Ethicon, Inc. High glass transition temperature absorbable microspheres
ES2344440T3 (es) 2006-11-09 2010-08-26 Orexigen Therapeutics, Inc. Formulaciones farmaceuticas en capas que comprenden una capa intermedia de disolucion rapida.
KR20140088619A (ko) * 2006-11-09 2014-07-10 오렉시젠 세러퓨틱스 인크. 단위 용량 팩키지
WO2008097850A1 (en) * 2007-02-02 2008-08-14 Warner Chilcott Company, Inc. Tretracycline compositions for topical administration
WO2008097851A1 (en) * 2007-02-02 2008-08-14 Warner Chilcott Company, Inc. Tetracycline compositions for topical administration
GB0714223D0 (en) * 2007-07-20 2007-08-29 Fujifilm Mfg Europe Bv Preparation of fine particles
US7976489B2 (en) 2007-12-04 2011-07-12 Orapharma, Inc. Device for delivering medicinal implants
US7976491B2 (en) * 2007-12-04 2011-07-12 Orapharma, Inc. Actuators for device for delivering medicinal implants
US7976490B2 (en) * 2007-12-04 2011-07-12 Orapharma, Inc. Medicinal implant cartridge
US20110144145A1 (en) * 2008-05-30 2011-06-16 Orexigen Therapeutics, Inc. Methods for treating visceral fat conditions
WO2010065317A1 (en) 2008-12-02 2010-06-10 Orapharma, Inc. Medicinal implant device and cartridge
US8333729B2 (en) * 2009-04-07 2012-12-18 Polybiotics Llc Multi-dose delivery system
CN102724878A (zh) 2010-01-11 2012-10-10 奥雷西根治疗公司 在重度抑郁症患者中提供体重减轻疗法的方法
US9119793B1 (en) 2011-06-28 2015-09-01 Medicis Pharmaceutical Corporation Gastroretentive dosage forms for doxycycline
RU2514111C2 (ru) * 2012-05-03 2014-04-27 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования Курская государственная сельскохозяйственная академия имени профессора И.И. Иванова Министерства сельского хозяйства Российской Федерации Способ получения микрокапсул лекарственных препаратов группы цефалоспоринов в полудане
RU2508095C2 (ru) * 2012-05-10 2014-02-27 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования Курская государственная сельскохозяйственная академия имени профессора И.И. Иванова Министерства сельского хозяйства Российской Федерации Способ получения микрокапсул лекарственных препаратов группы цефалоспоринов в конжаковой камеди в тетрагидрофуране
RU2514113C2 (ru) * 2012-05-25 2014-04-27 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования Курская государственная сельскохозяйственная академия имени профессора И.И. Иванова Министерства сельского хозяйства Российской Федерации Способ получения микрокапсул лекарственных препаратов группы цефалоспоринов в конжаковой камеди
PE20150358A1 (es) 2012-06-06 2015-04-06 Orexigen Therapeutics Inc Metodos para el tratamiento del sobrepeso y de la obesidad
US10842802B2 (en) 2013-03-15 2020-11-24 Medicis Pharmaceutical Corporation Controlled release pharmaceutical dosage forms
KR20160099081A (ko) 2013-07-26 2016-08-19 업데이트 파마 인코포레이트 비산트렌의 치료 효과 개선용 조합 방법
US9402701B2 (en) 2013-10-22 2016-08-02 Profounda, Inc Positionable delivery device and method

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS528795B2 (ko) * 1971-12-30 1977-03-11
US4107072A (en) * 1973-05-25 1978-08-15 Merck & Co., Inc. Process of isolating cyclohexane-free ethylcellulose microcapsules
US4107071A (en) * 1977-02-16 1978-08-15 Capsulated Systems, Inc. Method of producing microcapsules and resulting product
US4732763A (en) * 1978-10-17 1988-03-22 Stolle Research And Development Corporation Active/passive immunization of the internal female reproductive organs
CA1143289A (en) * 1978-10-17 1983-03-22 Lee R. Beck Microparticle drug delivery system
US4389330A (en) * 1980-10-06 1983-06-21 Stolle Research And Development Corporation Microencapsulation process
PH19942A (en) * 1980-11-18 1986-08-14 Sintex Inc Microencapsulation of water soluble polypeptides
US4675189A (en) * 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
IE52535B1 (en) * 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
EP0092918B1 (en) * 1982-04-22 1988-10-19 Imperial Chemical Industries Plc Continuous release formulations
CH660302A5 (fr) * 1984-10-17 1987-04-15 Debiopharm Sa Procede de micro-encapsulation en phase heterogene de substances medicamenteuses hydrosolubles.
JPH0751496B2 (ja) * 1986-04-02 1995-06-05 武田薬品工業株式会社 リポソ−ムの製造法

Also Published As

Publication number Publication date
ZA883737B (en) 1989-02-22
CA1330533C (en) 1994-07-05
AU1659288A (en) 1988-12-01
IL86274A (en) 1992-03-29
DE3867313D1 (de) 1992-02-13
NO177984B (no) 1995-09-25
NO177984C (no) 1996-01-03
ES2038236T3 (es) 1993-07-16
DK285088D0 (da) 1988-05-25
EP0292710A3 (en) 1989-03-22
NO882277L (no) 1988-11-28
JPS63307813A (ja) 1988-12-15
PH27019A (en) 1993-02-01
IE61338B1 (en) 1994-11-02
IE881565L (en) 1988-11-26
AU618000B2 (en) 1991-12-12
HK116493A (en) 1993-11-05
IL86274A0 (en) 1988-11-15
NZ224722A (en) 1990-04-26
KR970001209B1 (ko) 1997-02-04
BR1100810A (pt) 1999-10-13
US5000886A (en) 1991-03-19
DK285088A (da) 1988-11-27
DK169119B1 (da) 1994-08-22
GR3004186T3 (ko) 1993-03-31
JP2712101B2 (ja) 1998-02-10
ATE70992T1 (de) 1992-01-15
NO882277D0 (no) 1988-05-25
EP0292710A2 (en) 1988-11-30
EP0292710B1 (en) 1992-01-02

Similar Documents

Publication Publication Date Title
KR880013553A (ko) 개선된 상 분리 마이크로캡슐화 방법 및 그로부터 제조된 제약학적 조성물
RU2053769C1 (ru) Лекарственная композиция
AU602931B2 (en) Coating membrane and compositions prepared therefrom
ATE77946T1 (de) Injizierbares langwirkendes mikroteilchenpr|parat zur verabreichung entzuendungshemmender mittel.
EP0212751B1 (en) Process for the microencapsulation of a medicament, medicament so prepared and pharmaceutical compositions comprising it
KR890007739A (ko) 안정화된 의약물질, 이의 제조방법, 및 안정한 의약제제
DE2611143A1 (de) Biologisches material, seine verwendung und herstellung
GB1018125A (en) Chemical products
EP0461630A3 (en) Production process of microspheres
ATE66372T1 (de) Mikropartikel, bestehend aus einem biodegradierbaren, die freisetzung eines antimalaria-wirkstoffs kontrollierenden polymer, diese enthaltende pharmazeutische zusammensetzungen und ihr herstellungsverfahren.
GB2165517A (en) Micro-encapsulation of medicaments
EP0687466A1 (en) Homeopathic formulations
AU566228B2 (en) Compressed hydroxybutryic acid polymer retarded release vehicle
SU1375114A3 (ru) Способ получени средства продленного действи
EP1058542B1 (de) Verfahren zur herstellung von ummantelten, sphärischen granulatkörnern enthaltend prostan-derivate
DE3687807D1 (de) Sphaerische poly(alpha-aminosaeure)koerner und verfahren zu deren herstellung.
ZA892871B (en) Microbeads of ditiazem a process for their manufacture and a sustained-release pharmaceutical composition containing them
DE19741114A1 (de) Feuchtigkeitsstabile und magensaftresistente Arzneiformen für Tiere
JP3623805B2 (ja) ヒドロモルホンスフェロイド調整放出製剤
US4280995A (en) Oral suspension of phenytoin
DE1925229A1 (de) Prostansaeurederivate und Verfahren zu ihrer Herstellung
US3130125A (en) Preparation of medicated benzyl dextran gradual release therapeutic products containing up to five percent benzyl alcohol
TH4208A (th) การเตรียมเภสัชภัณฑ์ชนิดใหม่ที่มีการปลดปล่อยโดยควบคุมของสารประกอบที่ออกฤทธิ์และวิธีสำหรับการผลิตเภสัชภัณฑ์ดังกล่าว
KR950703947A (ko) 고형 의약용 조성물의 제조방법(method of manufacturing composition for solid medicine)

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
G160 Decision to publish patent application
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20110201

Year of fee payment: 15

EXPY Expiration of term